ICU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SeaStar Medical Holding Corp (ICU) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive developments, such as the publication of clinical results and a significant YoY revenue increase, the company's financial performance remains weak with declining net income, EPS, and gross margin. Additionally, technical indicators suggest the stock is overbought, and there are no strong proprietary trading signals or recent news catalysts to justify immediate action.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is at 80.536, signaling the stock is overbought. The price is near resistance levels (R1: 2.665 and R2: 2.785), suggesting limited upside potential in the short term. Moving averages are converging, indicating a lack of clear trend direction.
The publication of positive early post-approval clinical experience from the use of QUELIMMUNE therapy in a peer-reviewed journal. Revenue increased by 169.12% YoY in Q3 2025.
Declining financial metrics, including a drop in net income (-22.47% YoY), EPS (-87.96% YoY), and gross margin (-7.65% YoY). The stock is overbought based on RSI, and there is no recent news or significant trading trends to support a strong buy decision.
In Q3 2025, revenue increased to $183,000 (up 169.12% YoY). However, net income dropped to -$3,472,000 (-22.47% YoY), EPS fell to -1.32 (-87.96% YoY), and gross margin decreased to 92.35% (-7.65% YoY).
Maxim recently lowered the price target from $10 to $6 while maintaining a Buy rating, citing share dilution despite positive clinical results. This reflects cautious optimism but highlights concerns about the company's financial health and valuation.
